Following U.S. Stocks were among the “Top Losers” during Friday’s trade: Brandywine Realty Trust (NYSE:BDN), Magnum Hunter Resources Corp(NYSE:MHR), Keryx Biopharmaceuticals Inc. (KERX), Rex Energy Corporation (NASDAQ:REXX)
Their insights are depicted underneath:
Brandywine Realty Trust (NYSE:BDN) shares declined -4.93%, and closed at $14.86.
Brandywine Realty Trust (BDN), declared that the Corporation took part in a roundtable presentation at the Citi 2015 Global Property CEO Conference. The presentation took place on Tuesday, March 3, 2015.
Brandywine Realty Trust is one of the largest, publicly traded, full-service, integrated real estate companies in the United States. Organized as a real estate investment trust and operating in select markets, Brandywine owns, leases and manages an urban, town center office portfolio comprising 286 properties and 34.1 million square feet as of December 31, 2014.
Magnum Hunter Resources Corp(NYSE:MHR) dipped -4.91%, and closed at $2.52.
According to Marketwired, Magnum Hunter Resources Corp. (MHR), declared that the Corporation has designated Charlie Gibson as Vice President of Reservoir Engineering effective March 2, 2015. Mr. Gibson, age 56, will report to Gary C. Evans, Chairman & CEO of Magnum Hunter.
Mr. Gibson brings more than 30 years of engineering experience, counting operations, reservoir and reserve reporting, primarily within growth oriented oil and natural gas companies. Preceding to joining Magnum Hunter, Mr. Gibson served as Senior Vice President of Production Operations at Denbury Resources, Inc. since June 2014. During his twelve year tenure at Denbury, he held many managerial positions counting Senior Vice President of Planning, Technology and Business Development, Vice President of its West Region and Vice President of Reservoir Engineering and Geology. Mr. Gibson was a key participant in Denbury’s noteworthy business decisions. He was also involved in its analysis of potential attainments and integral to its reserve engineering process. Preceding to joining Denbury, Mr. Gibson served in various reservoir and engineering roles at Coho Resources and ORYX Energy. Mr. Gibson earned a Bachelor of Science in Petroleum Engineering degree from Louisiana State University.
Mr. Gary C. Evans, Chairman of the Board and Chief Executive Officer of Magnum Hunter Resources, commented, “We welcome Charlie to our organization. His vast knowledge and experience in reservoir engineering is exactly what we have been looking for since last year. He will be an integral part of our senior administration team.”
Magnum Hunter Resources Corporation and auxiliaries are a Houston, Texas based independent exploration and production corporation engaged in the attainment, development and production of crude oil, natural gas and natural gas liquids, primarily in the states of West Virginia and Ohio. The Corporation is presently active in two of the most prolific unconventional shale resource plays in North America, the Marcellus Shale and Utica Shale located in Northwest West Virginia and Southeast Ohio.
According to GLOBE NEWSWIRE, Keryx Biopharmaceuticals Inc. (KERX), declared the publication of Auryxia(TM) (ferric citrate) data and expert analyses in two peer-reviewed journals. An analysis of the effect of Auryxia on intravenous (IV) iron and erythropoiesis-stimulating agent (ESA) dosage and utilization was published online recently in the Journal of the American Society of Nephrology (JASN). Auryxia was approved by the U.S. Food and Drug Administration in September 2014 for the control of serum phosphorus levels in chronic kidney disease (CKD) patients on dialysis.
The publication in JASN, titled “Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD” was led by Kausik Umanath, MD, Division of Nephrology and Hypertension at Henry Ford Hospital. The analysis was based on the Phase 3 long-term safety and efficacy trial of Auryxia in dialysis-dependent CKD patients. The primary data from this study was published in 2014 in the Journal of the American Society of Nephrology.
Keryx Biopharmaceuticals, headquartered in New York, is focused on bringing innovative therapies to market for patients with renal disease. In December 2014, the Corporation launched its first FDA-approved product, Auryxia (ferric citrate) for the treatment of elevated serum phosphorus levels in patients with chronic kidney disease on dialysis, in the United States.
Rex Energy Corporation (NASDAQ:REXX) dropped - 4.71%, and closed at $4.65.
According to GLOBE NEWSWIRE, Rex Energy Corporation (REXX), declared its fourth quarter and full year 2014 operational and financial results.
Rex Energy had another year of successfully executing its strategy of improving performance, and increasing production and proved reserves through the drill-bit. Rigorous focus on cost control and operations has resulted in the corporation being among the best in the Marcellus on efficiently replacing reserves with low finding and development costs.
Production for 2014 averaged 154.4 MMcfe/d per day, a 66% raise over 2013. Fourth quarter 2014 production raised 15% over the third quarter of 2014 to 196.0 MMcfe/d per day, a record high for Rex Energy and was 78% higher than the preceding year period. Oil and natural gas liquids (“NGLs”) raised 16% over the third quarter of 2014 and was also a record level for the corporation. Proved reserves raised 57% year-over-year to 1.3 Tcfe. Drill-bit finding and development cost averaged $0.67 per Mcfe, while drill-bit finding and development cost in the Butler Operated Area was $0.41 per Mcfe.
Rex Energy is headquartered in State College, Pennsylvania and is an independent oil and gas exploration and production corporation operating in the Appalachian Basin and Illinois Basins within the United States. The corporation’s strategy is to pursue its higher potential exploration drilling prospects while acquiring oil and natural gas properties complementary to its portfolio.
